Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB39G in Advanced Malignant Solid Tumours
NCT07077252Phase 2Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Jul 2025
- Primary completion
- Sep 2027
- Modality
- Trispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB39G in advanced malignant solid tumor, sponsored by Sinocelltech Group Limited. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
SCTB39G
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT07077252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077252.